100 related articles for article (PubMed ID: 6574535)
1. Bromocriptine therapy in chronic schizophrenia: effects on symptomatology, sleep patterns, and prolactin response to stimulation.
Brambilla F; Scarone S; Pugnetti L; Massironi R; Penati G; Nobile P
Psychiatry Res; 1983 Mar; 8(3):159-69. PubMed ID: 6574535
[TBL] [Abstract][Full Text] [Related]
2. Acute and subchronic effects of low-dose bromocriptine in haloperidol-treated schizophrenics.
Gattaz WF; Rost W; Hübner CK; Bauer K
Biol Psychiatry; 1989 Feb; 25(3):247-55. PubMed ID: 2643996
[TBL] [Abstract][Full Text] [Related]
3. Basal and haloperidol-stimulated prolactin in neuroleptic-free men with schizophrenia defined by 11 diagnostic systems.
Keks NA; Copolov DL; Kulkarni J; Mackie B; Singh BS; McGorry P; Rubin RT; Hassett A; McLaughlin M; van Riel R
Biol Psychiatry; 1990 Jun; 27(11):1203-15. PubMed ID: 2354227
[TBL] [Abstract][Full Text] [Related]
4. [Effect of high single doses of bromocriptine in schizophrenic patients with elevated serum prolactin levels and extrapyramidal side effects associated with neuroleptic treatment (author's transl)].
Ringwald E; Lustig A; Moscovici M; Spiegel R; Vamos E
Pharmakopsychiatr Neuropsychopharmakol; 1980 Nov; 13(6):318-24. PubMed ID: 6111093
[TBL] [Abstract][Full Text] [Related]
5. Serum prolactin as a correlate of clinical response to haloperidol.
Van Putten T; Marder SR; Mintz J
J Clin Psychopharmacol; 1991 Dec; 11(6):357-61. PubMed ID: 1770154
[TBL] [Abstract][Full Text] [Related]
6. Prolactin responses to haloperidol in drug-free and treated schizophrenic patients.
Markianos M; Sakellariou G; Bistolaki E
J Neural Transm Gen Sect; 1991; 83(1-2):37-42. PubMed ID: 2018629
[TBL] [Abstract][Full Text] [Related]
7. Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements during maintenance haloperidol treatment in male patients with schizophrenia.
Newcomer JW; Riney SJ; Vinogradov S; Csernansky JG
Psychiatry Res; 1992 Mar; 41(3):191-202. PubMed ID: 1594706
[TBL] [Abstract][Full Text] [Related]
8. The Dose Reduction in Schizophrenia (DORIS) Study: a final report.
Hirschowitz J; Hitzemann R; Piscani K; Burr G; Frecska E; Culliton D; Mann M; Curtis C
Schizophr Res; 1997 Jan; 23(1):31-43. PubMed ID: 9050126
[TBL] [Abstract][Full Text] [Related]
9. [Comparative efficacy of bromocriptine, carbamazepine and cyproheptadine with neuroleptics in 24 refractory chronic schizophrenic patients].
Llorca PM; Wolf MA; Lançon C; Bougerol T
Encephale; 1993; 19(5):565-71. PubMed ID: 8306925
[TBL] [Abstract][Full Text] [Related]
10. Characterization of ergot and non-ergot serotonin antagonists by prolactin and growth hormone profiles during wakefulness and sleep.
Clarenbach P; Del Pozo E; Brownell J; Heredia E; Spiegel R; Cramer H
Brain Res; 1980 Dec; 202(2):357-63. PubMed ID: 7437907
[TBL] [Abstract][Full Text] [Related]
11. Effect of low-dose bromocriptine in treatment of psychosis: the dopamine autoreceptor-stimulation strategy.
Meltzer HY; Kolakowska T; Robertson A; Tricou BJ
Psychopharmacology (Berl); 1983; 81(1):37-41. PubMed ID: 6415730
[TBL] [Abstract][Full Text] [Related]
12. Effects of treatment with various doses of haloperidol on the pituitary-gonadal axis in male schizophrenic patients.
Rinieris P; Hatzimanolis J; Markianos M; Stefanis C
Neuropsychobiology; 1989; 22(3):146-9. PubMed ID: 2485861
[TBL] [Abstract][Full Text] [Related]
13. Low dose bromocriptine: a study of acute effects in chronic mediated schizophrenics.
Cutler NR; Jeste DV; Kaufmann CA; Karoum F; Schran HF; Wyatt RJ
Prog Neuropsychopharmacol Biol Psychiatry; 1984; 8(2):277-83. PubMed ID: 6146164
[TBL] [Abstract][Full Text] [Related]
14. Haloperidol. Plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical v radioreceptor plasma level assays.
Smith RC; Baumgartner R; Misra CH; Mauldin M; Shvartsburd A; Ho BT; DeJohn C
Arch Gen Psychiatry; 1984 Nov; 41(11):1044-9. PubMed ID: 6497566
[TBL] [Abstract][Full Text] [Related]
15. Haloperidol decanoate in schizophreniform disorders. Clinical and neuroendocrine aspects.
Meco G; Casacchia M; Attenni M; Iafrate A; Castellana F; Ecari U
Acta Psychiatr Belg; 1983; 83(1):57-68. PubMed ID: 6613612
[TBL] [Abstract][Full Text] [Related]
16. Bromocriptine in augmentation of antipsychotic response in chronic schizophrenia: a negative pilot report.
Wells BG; Chu CC; Abi-Darghum A; Saini TS
Pharmacopsychiatry; 1991 Jul; 24(4):118-20. PubMed ID: 1684441
[TBL] [Abstract][Full Text] [Related]
17. Effect of propranolol treatment on serum prolactin level in schizophrenic patients.
Elizur A; Segal Z; Yeret A; Ben-David M
Commun Psychopharmacol; 1980; 4(3):203-6. PubMed ID: 7226751
[No Abstract] [Full Text] [Related]
18. Relationship of psychotic symptoms to haloperidol-stimulated prolactin release.
Kulkarni J; Keks NA; Stuart G; Mackie B; Minas IH; Singh BS; Copolov DL
Acta Psychiatr Scand; 1990 Oct; 82(4):271-4. PubMed ID: 2260479
[TBL] [Abstract][Full Text] [Related]
19. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation.
Chouinard G; Safadi G; Beauclair L
J Clin Psychopharmacol; 1994 Dec; 14(6):377-84. PubMed ID: 7884017
[TBL] [Abstract][Full Text] [Related]
20. Neuroendocrine tests during treatment with neuroleptic drugs I. Plasma prolactin response to haloperidol challenge.
Kolakowska T; Braddock L; Wiles D; Franklin M; Gelder M
Br J Psychiatry; 1981 Nov; 139():400-4. PubMed ID: 6120731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
